Related Experiment Video
Updated: Jul 16, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Radiosensitization effect of PD-L1-targeted small molecules with direct antitumor activity on non-small cell lung
Cun Gao1, Xiangyang Sun2, Jiankun Song3
1Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250200, China.
Abstract:
In this study, we evaluated the combined effects of X-ray irradiation and compounds with PD-L1 downregulation activity (N01-N04) in non-small cell lung cancer (NSCLC) cell lines (HCC78 and H2122), identifying the inhibitor N02 for its superior binding affinity and stability. ELISA assays confirmed that N02 directly blocks the PD-1/PD-L1 interaction with an IC50 of 55.11 ± 6.14 nM. Functional assays, including CCK-8, colony formation, scratch wound healing, and transwell invasion, demonstrated that N02 synergized with radiation to suppress cell viability more potently, clonogenic survival, migration, invasion, and apoptosis compared to either treatment alone. Western blot and qPCR analyses revealed that N02, particularly in combination with radiation, downregulated PD-L1 expression and modulated proteins associated with proliferation and apoptosis. In vivo experiments further validated that the N02-radiation combination significantly inhibited tumor growth. These findings suggest that combining radiotherapy with the compound N02 represents a promising therapeutic strategy to enhance treatment efficacy in NSCLC.
Insights
Combining X-ray radiation with compound N02, a PD-L1 inhibitor, significantly enhances non-small cell lung cancer (NSCLC) treatment by suppressing tumor growth and improving therapeutic efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Radiotherapy
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
- The PD-1/PD-L1 pathway is a critical target for cancer immunotherapy.
- Radiotherapy is a standard treatment for NSCLC, but resistance can occur.
Purpose of the Study:
- To evaluate the synergistic effects of X-ray irradiation and PD-L1 downregulation compounds in NSCLC.
- To identify and characterize a potent PD-L1 inhibitor (N02) for combination therapy.
- To assess the efficacy of combining N02 with radiotherapy in preclinical NSCLC models.
Main Methods:
- Screening of PD-L1 inhibitors (N01-N04) in NSCLC cell lines (HCC78, H2122).
- ELISA to confirm N02's direct blockade of PD-1/PD-L1 interaction (IC50 determination).
- In vitro functional assays (CCK-8, colony formation, migration, invasion) and molecular analyses (Western blot, qPCR).
- In vivo tumor growth inhibition studies in animal models.
Main Results:
- Compound N02 demonstrated superior binding affinity and stability, directly inhibiting PD-1/PD-L1 interaction with an IC50 of 55.11 ± 6.14 nM.
- N02 synergized with radiation to significantly suppress NSCLC cell viability, clonogenic survival, migration, invasion, and induce apoptosis.
- Combination therapy downregulated PD-L1 expression and modulated key proteins involved in proliferation and apoptosis.
- In vivo studies confirmed significant inhibition of tumor growth by the N02-radiation combination.
Conclusions:
- The combination of radiotherapy and compound N02 shows significant therapeutic potential for NSCLC.
- N02 acts as a potent PD-L1 inhibitor, enhancing the anti-tumor effects of radiation.
- This combination strategy warrants further investigation as a novel treatment approach for NSCLC.
